Accurexa Inc. (ACXA) 1.3500 $ACXA
Accurexa Appoints William Callahan to Its Board of Directors
ACCESSWIRE - Thu Jul 02, 7:00AM CDT
NEWARK, DE / ACCESSWIRE / July 2, 2015 / Accurexa Inc. (the "Company"
(OTCQB: ACXA), a biotechnology company focused on developing and commercializing novel neurological therapies, announced today that William Callahan has been appointed to its Board of Directors, effective July 1, 2015.
DEPO: 30.14 (+2.03)
"New To The Street" Introduces Five Companies on the Next Two Shows
Marketwired - Thu Jun 25, 8:02AM CDT
"New To The Street" just completed shooting two shows in their state of the art NYC studios.
Accurexa Announces Equity Financing of $2.25 Million
ACCESSWIRE - Wed Jun 17, 7:01AM CDT
SAN FRANCISCO, CA / ACCESSWIRE / June 17, 2015 / Accurexa Inc. ("Accurexa" or the "Company" , (OTCQB: ACXA), a biotechnology company focused on developing and commercializing novel neurological therapies, today announced that it has entered into definitive agreements with institutional investors, led by a healthcare dedicated fund, for the private placement of 2,250 shares of the Company's convertible preferred stock for gross proceeds to the Company of $2,250,000.
Accurexa Files 501(k) with FDA; Share Skyrocket to 2015 Highs - Analyst Brief by BrokerBank Securities
PR Newswire - Wed Jun 17, 6:00AM CDT
Accurexa Inc. (OTCQB: ACXA) a biotechnology company focused on developing and commercializing novel neurological therapies, announced on Monday that it has filed a submission with the U.S. FDA for 510(k) clearance to market its BranchPoint device. The Company's BranchPoint device was invented to deliver therapeutics, such as stem cells, through the radial deployment of a flexible catheter to specific brain target areas through a single brain penetration. The current standard of care is the use of straight, rigid needles which increase the risk of bleeding, stroke or reflux of therapeutics. Accurexa's system helps minimize this risk.
Accurexa Submits its BranchPoint Device to FDA for 510(k) Clearance
ACCESSWIRE - Mon Jun 15, 7:00AM CDT
SAN FRANCISCO, CA / ACCESSWIRE / June 15, 2015 / Accurexa Inc. (the "Company" (OTCQB: ACXA), a biotechnology company focused on developing and commercializing novel neurological therapies, announced today that it has filed a submission with the U.S. Food and Drug Administration (FDA) for 510(k) clearance to market its BranchPoint device.
Stem Cell Stock Review Updates Coverage On Accurexa
ACCESSWIRE - Fri Jun 12, 9:00AM CDT
BEVERLY HILLS, CA / ACCESSWIRE / June 12, 2015 / The Stem Cell Stock Review has updated coverage on the company and will be providing ongoing coverage. Roland Rick Perry, Editor of the Review stated "Accurexa's end goal is to provide a medical device that can save lives - not by improving the therapeutics or drugs used to treat neurological disorders including brain tumors, but rather by improving the delivery method and effectiveness of currently approved drugs - used to treat the disorders using a flexible delivery catheter." Adding, "The device called "Branchpoint" is designed to permit Clinicians to "tailor" therapeutic delivery and give physicians more precise control of the volume of therapeutics delivered and ensure that therapeutics delivered into the brain stay in the brain, avoiding the problem of reflux out to the brain surface. We are excited to update coverage as they progress towards their filing a 510k submission with the FDA."
These Small-Cap Stocks Continue to Surge as Dow Heads Higher
ACCESSWIRE - Wed Jun 03, 11:19AM CDT
CORAL GABLES, FL / ACCESSWIRE / June 3, 2015 / Wednesday morning the Dow Jones Industrial average headed higher and tested new highs for the month of June, attempting to break a 2-week downtrend, which began late in May. The Dow held levels above 18,151 through the early morning session as positive sentiment rang through the markets. According to CNN's Fear/Greed Index, "Stocks have outperformed bonds by 2.85 percentage points during the last 20 trading days. This is close to the strongest performance for stocks relative to bonds in the past two years and indicates investors are rotating into stocks from the relative safety of bonds."
From Pest Control To Biotech, Summer Hasn't Slowed For Many Penny Stocks
ACCESSWIRE - Tue Jun 02, 9:59AM CDT
CORAL GABLES, FL / ACCESSWIRE / June 2, 2015 / Historically summer months have meant the "slow season" for active traders in the stock market. Vacations, family outings, and simply taking time off have all been reasons for attention to be focused on anything but the stock market. This year however may be a bit different as the outlook on consumer spending suggests that money is being socked away versus being used for consumer goods. U.S. consumer spending growth mysteriously put the breaks on in April when households simply cut back on purchases of things like automobiles and opted instead to build savings.
CDTI: 1.81 (+0.04)
Are Any Of These On Your 'Penny Stocks To Watch' List
ACCESSWIRE - Mon Jun 01, 10:27AM CDT
CORAL GABLES, FL / ACCESSWIRE / June 1, 2015 / Monday morning saw US stock futures climb suggesting a positive open for Wall Street on the first day of the month. Healthcare and biotechnology stocks have helped to spur new bullish sentiment heading into the summer months and even though the markets closed weaker during the final days of May, June may be seeing a rebound. More volatile stocks like those in biotech have taken on a bigger focus in the markets in 2015 and it's not just he bigger stocks seeing this either. Penny stocks, which are inherently volatile, have also seen activity bolstered even during these early summer months. The likes of Oncothyreon, Inc. (NASDAQ: ONTY), Coastal Integrated Services, Inc. (PINKSHEETS: COLV), and Accurexa, Inc. (OTCQB: ACXA) have all seen relative increases in market activity during the more recent weeks of trading.
ONTY: 3.66 (+0.04)
What Biotechnology Stocks Will Be Next To Enjoy The Bull Market?
ACCESSWIRE - Fri May 29, 6:44AM CDT
CORAL GABLES, FL / ACCESSWIRE / May 29, 2015 / The Nasdaq Biotechnology Index is up significantly over the last 5 years with a good majority of positive momentum kicking in during the last 18 months. Since levels hovering around 830 this time in 2010, you can quickly begin to see the massive growth that this market has seen especially since the NBI hit over 3,900 this year. The sharpest increase on the index hasn't been until recently from 2014- present and with the amount of IPO's and mergers & acquisitions buzz, biotech stocks have captured the interests of many. Oncothyreon, Inc. (ONTY), Amarin Corp. Plc (AMRN), and Accurexa Inc. (ACXA) have begun to become more familiar with today's biotech investors.
AMRN: 2.41 (+0.02), ONTY: 3.66 (+0.04)
Accurexa's First "New To The Street" Interview on YouTube
ACCESSWIRE - Mon Apr 06, 6:15PM CDT
SAN FRANCISCO, CA / ACCESSWIRE / April 6, 2015 / Accurexa Inc. (the "Company" (OTCQB:ACXA), a biotechnology company focused on developing and commercializing novel neurological therapies, announced today that its first "New To The Street" interview was aired nationwide and is available on YouTube under the following link (https://www.youtube.com/watch?v=7tUYtz7WV2U).
Accurexa's BranchPoint Demonstrates Feasibility of Convection-Enhanced Delivery
ACCESSWIRE - Mon Mar 23, 7:01AM CDT
SAN FRANCISCO, CA / ACCESSWIRE / March 23, 2015 / Accurexa Inc. (the "Company" (OTCQB:ACXA), a biotechnology company focused on developing and commercializing novel neurological therapies, reported that its BranchPoint technology has been tested for its ability to deploy a Convection-Enhanced Delivery (CED) catheter that is compatible for use with intraoperative Magnetic Resonance Imaging (iMRI) guidance. This feasibility testing of CED with the BranchPoint technology supports the Company's ACX-31 development program which could deliver temozolomide, a chemotherapy drug, directly to the tumor site with the Company's BranchPoint device. Temozolomide is a generic, approved chemotherapy drug that is indicated for the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment. Before temozolomide became generic, it generated US sales of $420 million and global sales of $910 million under its brand name Temodar in 2012.
"New To The Street" to Air First of a 6 Part Series Featuring Accurexa, Inc. (ACXA)
Marketwired - Wed Mar 18, 9:49AM CDT
"New To The Street" just completed a full 11 minute in-depth interview with George Yu, President and CEO of Accurexa Inc. (OTCQB: ACXA) and its BranchPoint Device.
DSKX: 3.18 (-0.05)
FDA Approves Accurexa's Small Business Qualification
ACCESSWIRE - Mon Mar 16, 7:03AM CDT
SAN FRANCISCO, CA / ACCESSWIRE / March 16, 2015 / Accurexa Inc. (the "Company" (OTCQB:ACXA), a biotechnology company focused on developing and commercializing novel neurological therapies, announced today that the U.S. FDA (Food and Drug Administration) informed the Company that it qualifies under MDUFA (Medical Device User Fee Amendment) as a Small Business for a reduced or waived fee for medical device submissions made during fiscal year 2015. The Company's Small Business status expires at the close of business September 30, 2015.
Accurexa's Licensed Patent Application Enters National Phase
ACCESSWIRE - Mon Mar 09, 7:01AM CDT
SAN FRANCISCO, CA / ACCESSWIRE / March 9, 2015 / Accurexa Inc. (the "Company" (OTCQB:ACXA), a biotechnology company focused on developing and commercializing novel neurological therapies, announced today that the U.S. Patent Application No. PCT/US2013/052301, Microinjection Catheter; UC Case No. SF2012-063, which the Company exclusively licensed from the University of California, San Francisco (UCSF), has entered national phase applications in the US, European Union, Japan, Canada and China.
Accurexa's BranchPoint Device Delivering Dopaminergic Stem Cells Published in Molecular Therapy
ACCESSWIRE - Thu Feb 12, 7:00AM CST
SAN FRANCISCO, CA / ACCESSWIRE / February 12, 2015 / Accurexa Inc. (the "Company" (OTCQB: ACXA), a biotechnology company focused on developing and commercializing novel neurological therapies, announced today that its BranchPoint device was published in a scientific publication in Molecular Therapy, the official journal of the American Society for Gene & Cell Therapy. Accurexa's BranchPoint device successfully demonstrated the feasibility of delivering human embryonic stem cell-derived dopaminergic neurons in a large animal study. BranchPoint's intracerebral cell transplantation deployed cells to multiple target locations at variable radial distances and depths along the initial brain penetration tract with real-time interventional magnetic resonance image (iMRI) guidance, which can be critical in the treatment of Parkinson's Disease.
Accurexa Initiates Development of Chemotherapy Product for Brain Cancer
ACCESSWIRE - Wed Feb 04, 7:31AM CST
SAN FRANCISCO,CA / ACCESSWIRE / February 4, 2015 / Accurexa Inc. (the "Company" (OTCQB: ACXA), a biotechnology company focused on developing and commercializing novel neurological therapies, announced today that it initiated the development of ACX-31 for the treatment of glioblastoma multiforme, a malignant primary brain tumor. ACX-31 is a chemotherapy product that delivers temozolomide directly to the tumor site with the Company's BranchPoint device. Temozolomide is a generic, approved chemotherapy drug that is indicated for the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment. The Company's BrainPoint device has been developed for the delivery of therapeutics directly into specific regions of the brain and is expected to obtain FDA regulatory approval through a 510(k) submission process.
Arrowhead Business and Investment Decisions Initiates Coverage on Accurexa Inc.
ACCESSWIRE - Thu Jan 22, 7:01AM CST
NEW YORK, NY / ACCESSWIRE / January 22, 2015 / Arrowhead Business and Investment Decisions, LLC ("Arrowhead" initiated coverage and published a Due Diligence and Valuation Report on Accurexa Inc. ("Accurexa" or the "Company" (OTCQB:ACXA), a biotechnology company focused on developing and commercializing novel neurological therapies, on December 23, 2014.
Accurexa Appoints William Callahan to Its Board of Directors
ACCESSWIRE - Thu Jul 02, 7:00AM CDT
NEWARK, DE / ACCESSWIRE / July 2, 2015 / Accurexa Inc. (the "Company"
(OTCQB: ACXA), a biotechnology company focused on developing and commercializing novel neurological therapies, announced today that William Callahan has been appointed to its Board of Directors, effective July 1, 2015. DEPO: 30.14 (+2.03)
"New To The Street" Introduces Five Companies on the Next Two Shows
Marketwired - Thu Jun 25, 8:02AM CDT
"New To The Street" just completed shooting two shows in their state of the art NYC studios.
Accurexa Announces Equity Financing of $2.25 Million
ACCESSWIRE - Wed Jun 17, 7:01AM CDT
SAN FRANCISCO, CA / ACCESSWIRE / June 17, 2015 / Accurexa Inc. ("Accurexa" or the "Company"
, (OTCQB: ACXA), a biotechnology company focused on developing and commercializing novel neurological therapies, today announced that it has entered into definitive agreements with institutional investors, led by a healthcare dedicated fund, for the private placement of 2,250 shares of the Company's convertible preferred stock for gross proceeds to the Company of $2,250,000. Accurexa Files 501(k) with FDA; Share Skyrocket to 2015 Highs - Analyst Brief by BrokerBank Securities
PR Newswire - Wed Jun 17, 6:00AM CDT
Accurexa Inc. (OTCQB: ACXA) a biotechnology company focused on developing and commercializing novel neurological therapies, announced on Monday that it has filed a submission with the U.S. FDA for 510(k) clearance to market its BranchPoint device. The Company's BranchPoint device was invented to deliver therapeutics, such as stem cells, through the radial deployment of a flexible catheter to specific brain target areas through a single brain penetration. The current standard of care is the use of straight, rigid needles which increase the risk of bleeding, stroke or reflux of therapeutics. Accurexa's system helps minimize this risk.
Accurexa Submits its BranchPoint Device to FDA for 510(k) Clearance
ACCESSWIRE - Mon Jun 15, 7:00AM CDT
SAN FRANCISCO, CA / ACCESSWIRE / June 15, 2015 / Accurexa Inc. (the "Company"
(OTCQB: ACXA), a biotechnology company focused on developing and commercializing novel neurological therapies, announced today that it has filed a submission with the U.S. Food and Drug Administration (FDA) for 510(k) clearance to market its BranchPoint device. Stem Cell Stock Review Updates Coverage On Accurexa
ACCESSWIRE - Fri Jun 12, 9:00AM CDT
BEVERLY HILLS, CA / ACCESSWIRE / June 12, 2015 / The Stem Cell Stock Review has updated coverage on the company and will be providing ongoing coverage. Roland Rick Perry, Editor of the Review stated "Accurexa's end goal is to provide a medical device that can save lives - not by improving the therapeutics or drugs used to treat neurological disorders including brain tumors, but rather by improving the delivery method and effectiveness of currently approved drugs - used to treat the disorders using a flexible delivery catheter." Adding, "The device called "Branchpoint" is designed to permit Clinicians to "tailor" therapeutic delivery and give physicians more precise control of the volume of therapeutics delivered and ensure that therapeutics delivered into the brain stay in the brain, avoiding the problem of reflux out to the brain surface. We are excited to update coverage as they progress towards their filing a 510k submission with the FDA."
These Small-Cap Stocks Continue to Surge as Dow Heads Higher
ACCESSWIRE - Wed Jun 03, 11:19AM CDT
CORAL GABLES, FL / ACCESSWIRE / June 3, 2015 / Wednesday morning the Dow Jones Industrial average headed higher and tested new highs for the month of June, attempting to break a 2-week downtrend, which began late in May. The Dow held levels above 18,151 through the early morning session as positive sentiment rang through the markets. According to CNN's Fear/Greed Index, "Stocks have outperformed bonds by 2.85 percentage points during the last 20 trading days. This is close to the strongest performance for stocks relative to bonds in the past two years and indicates investors are rotating into stocks from the relative safety of bonds."
From Pest Control To Biotech, Summer Hasn't Slowed For Many Penny Stocks
ACCESSWIRE - Tue Jun 02, 9:59AM CDT
CORAL GABLES, FL / ACCESSWIRE / June 2, 2015 / Historically summer months have meant the "slow season" for active traders in the stock market. Vacations, family outings, and simply taking time off have all been reasons for attention to be focused on anything but the stock market. This year however may be a bit different as the outlook on consumer spending suggests that money is being socked away versus being used for consumer goods. U.S. consumer spending growth mysteriously put the breaks on in April when households simply cut back on purchases of things like automobiles and opted instead to build savings.
CDTI: 1.81 (+0.04)
Are Any Of These On Your 'Penny Stocks To Watch' List
ACCESSWIRE - Mon Jun 01, 10:27AM CDT
CORAL GABLES, FL / ACCESSWIRE / June 1, 2015 / Monday morning saw US stock futures climb suggesting a positive open for Wall Street on the first day of the month. Healthcare and biotechnology stocks have helped to spur new bullish sentiment heading into the summer months and even though the markets closed weaker during the final days of May, June may be seeing a rebound. More volatile stocks like those in biotech have taken on a bigger focus in the markets in 2015 and it's not just he bigger stocks seeing this either. Penny stocks, which are inherently volatile, have also seen activity bolstered even during these early summer months. The likes of Oncothyreon, Inc. (NASDAQ: ONTY), Coastal Integrated Services, Inc. (PINKSHEETS: COLV), and Accurexa, Inc. (OTCQB: ACXA) have all seen relative increases in market activity during the more recent weeks of trading.
ONTY: 3.66 (+0.04)
What Biotechnology Stocks Will Be Next To Enjoy The Bull Market?
ACCESSWIRE - Fri May 29, 6:44AM CDT
CORAL GABLES, FL / ACCESSWIRE / May 29, 2015 / The Nasdaq Biotechnology Index is up significantly over the last 5 years with a good majority of positive momentum kicking in during the last 18 months. Since levels hovering around 830 this time in 2010, you can quickly begin to see the massive growth that this market has seen especially since the NBI hit over 3,900 this year. The sharpest increase on the index hasn't been until recently from 2014- present and with the amount of IPO's and mergers & acquisitions buzz, biotech stocks have captured the interests of many. Oncothyreon, Inc. (ONTY), Amarin Corp. Plc (AMRN), and Accurexa Inc. (ACXA) have begun to become more familiar with today's biotech investors.
AMRN: 2.41 (+0.02), ONTY: 3.66 (+0.04)
Accurexa's First "New To The Street" Interview on YouTube
ACCESSWIRE - Mon Apr 06, 6:15PM CDT
SAN FRANCISCO, CA / ACCESSWIRE / April 6, 2015 / Accurexa Inc. (the "Company"
(OTCQB:ACXA), a biotechnology company focused on developing and commercializing novel neurological therapies, announced today that its first "New To The Street" interview was aired nationwide and is available on YouTube under the following link (https://www.youtube.com/watch?v=7tUYtz7WV2U). Accurexa's BranchPoint Demonstrates Feasibility of Convection-Enhanced Delivery
ACCESSWIRE - Mon Mar 23, 7:01AM CDT
SAN FRANCISCO, CA / ACCESSWIRE / March 23, 2015 / Accurexa Inc. (the "Company"
(OTCQB:ACXA), a biotechnology company focused on developing and commercializing novel neurological therapies, reported that its BranchPoint technology has been tested for its ability to deploy a Convection-Enhanced Delivery (CED) catheter that is compatible for use with intraoperative Magnetic Resonance Imaging (iMRI) guidance. This feasibility testing of CED with the BranchPoint technology supports the Company's ACX-31 development program which could deliver temozolomide, a chemotherapy drug, directly to the tumor site with the Company's BranchPoint device. Temozolomide is a generic, approved chemotherapy drug that is indicated for the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment. Before temozolomide became generic, it generated US sales of $420 million and global sales of $910 million under its brand name Temodar in 2012. "New To The Street" to Air First of a 6 Part Series Featuring Accurexa, Inc. (ACXA)
Marketwired - Wed Mar 18, 9:49AM CDT
"New To The Street" just completed a full 11 minute in-depth interview with George Yu, President and CEO of Accurexa Inc. (OTCQB: ACXA) and its BranchPoint Device.
DSKX: 3.18 (-0.05)
FDA Approves Accurexa's Small Business Qualification
ACCESSWIRE - Mon Mar 16, 7:03AM CDT
SAN FRANCISCO, CA / ACCESSWIRE / March 16, 2015 / Accurexa Inc. (the "Company"
(OTCQB:ACXA), a biotechnology company focused on developing and commercializing novel neurological therapies, announced today that the U.S. FDA (Food and Drug Administration) informed the Company that it qualifies under MDUFA (Medical Device User Fee Amendment) as a Small Business for a reduced or waived fee for medical device submissions made during fiscal year 2015. The Company's Small Business status expires at the close of business September 30, 2015. Accurexa's Licensed Patent Application Enters National Phase
ACCESSWIRE - Mon Mar 09, 7:01AM CDT
SAN FRANCISCO, CA / ACCESSWIRE / March 9, 2015 / Accurexa Inc. (the "Company"
(OTCQB:ACXA), a biotechnology company focused on developing and commercializing novel neurological therapies, announced today that the U.S. Patent Application No. PCT/US2013/052301, Microinjection Catheter; UC Case No. SF2012-063, which the Company exclusively licensed from the University of California, San Francisco (UCSF), has entered national phase applications in the US, European Union, Japan, Canada and China. Accurexa's BranchPoint Device Delivering Dopaminergic Stem Cells Published in Molecular Therapy
ACCESSWIRE - Thu Feb 12, 7:00AM CST
SAN FRANCISCO, CA / ACCESSWIRE / February 12, 2015 / Accurexa Inc. (the "Company"
(OTCQB: ACXA), a biotechnology company focused on developing and commercializing novel neurological therapies, announced today that its BranchPoint device was published in a scientific publication in Molecular Therapy, the official journal of the American Society for Gene & Cell Therapy. Accurexa's BranchPoint device successfully demonstrated the feasibility of delivering human embryonic stem cell-derived dopaminergic neurons in a large animal study. BranchPoint's intracerebral cell transplantation deployed cells to multiple target locations at variable radial distances and depths along the initial brain penetration tract with real-time interventional magnetic resonance image (iMRI) guidance, which can be critical in the treatment of Parkinson's Disease. Accurexa Initiates Development of Chemotherapy Product for Brain Cancer
ACCESSWIRE - Wed Feb 04, 7:31AM CST
SAN FRANCISCO,CA / ACCESSWIRE / February 4, 2015 / Accurexa Inc. (the "Company"
(OTCQB: ACXA), a biotechnology company focused on developing and commercializing novel neurological therapies, announced today that it initiated the development of ACX-31 for the treatment of glioblastoma multiforme, a malignant primary brain tumor. ACX-31 is a chemotherapy product that delivers temozolomide directly to the tumor site with the Company's BranchPoint device. Temozolomide is a generic, approved chemotherapy drug that is indicated for the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment. The Company's BrainPoint device has been developed for the delivery of therapeutics directly into specific regions of the brain and is expected to obtain FDA regulatory approval through a 510(k) submission process. Arrowhead Business and Investment Decisions Initiates Coverage on Accurexa Inc.
ACCESSWIRE - Thu Jan 22, 7:01AM CST
NEW YORK, NY / ACCESSWIRE / January 22, 2015 / Arrowhead Business and Investment Decisions, LLC ("Arrowhead"
initiated coverage and published a Due Diligence and Valuation Report on Accurexa Inc. ("Accurexa" or the "Company" (OTCQB:ACXA), a biotechnology company focused on developing and commercializing novel neurological therapies, on December 23, 2014. 
